{"id":"W4389258214","doi":"10.1182/blood-2023-178804","title":"KB-Lanra 1001: A Phase 1b/2 Study of Safety, PK, PD, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib in Combination with the FLT3 Inhibitor Gilteritinib in FLT3-Mutated R/R AML","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Servier; Astellas Pharma; Genentech; Actuate Therapeutics; Sierra Oncology; Incyte; Ono Pharmaceutical; Mateon Therapeutics; Jazz Pharmaceuticals; Gilead Sciences; Actinium Pharmaceuticals; Karyopharm Therapeutics; Celgene; Bristol-Myers Squibb; AstraZeneca; Syndax Pharmaceuticals; Constellation Pharmaceuticals; Agios Pharmaceuticals; GlaxoSmithKline; Amgen","keywords":"Syk; Fms-Like Tyrosine Kinase 3; Cancer research; Tyrosine-kinase inhibitor; Medicine; Sorafenib; Tyrosine kinase; Myeloid leukemia; Pharmacology; Immunology; Internal medicine; Biology; Cancer; Receptor; Mutation; Biochemistry","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001714992,0.001935761,0.002052902,0.0007422323,0.0004166627,0.001518646,0.001232476,0.001337593,0.005185608],"category_scores_gemma":[0.0006668259,0.0008074747,0.001443101,0.0005154003,0.001205536,0.001223666,0.0003845677,0.003929359,0.001783321],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001539688,"about_ca_system_score_gemma":0.001749998,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001240525,"about_ca_topic_score_gemma":0.002889363,"domain_scores_codex":[0.9994988,0.0001792398,0.00002403702,0.0001062448,0.0000715796,0.0001199905],"domain_scores_gemma":[0.9995949,0.00004207185,0.00008329368,0.00004677318,0.00003414723,0.0001987806],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.315846,0.1812339,0.00585162,0.001933624,0.002407963,0.0008282455,0.0006384162,0.007899267,0.2679807,0.001043712,0.01239929,0.2019373],"study_design_scores_gemma":[0.2670185,0.6819549,0.01071399,0.00008230558,0.001040727,0.001559317,0.0001564175,0.00344553,0.02476592,0.0003828532,0.008751922,0.0001278059],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9885306,0.004630924,0.0008224424,0.0005022036,0.0001143823,0.001469547,0.001487184,0.0003493029,0.0020935],"genre_scores_gemma":[0.9846749,0.003675365,0.001834789,0.0007216394,0.0001141583,0.0014922,0.003592432,0.00008891604,0.003805485],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005185608,"threshold_uncertainty_score":0.01734757,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0158046776241552,"score_gpt":0.2981981579199156,"score_spread":0.2823934802957603,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}